This represents a potentially significant advancement for treating fatty liver disease, which affects an estimated 25% of adults globally
Phase 3 RCT (2024) : Chinese multicenter trial (n=458) demonstrating significant improvement in modified Toronto Clinical Neuropathy Score with ALC 1,500 mg/day vs
For research designs engaging this axis alongside Retatrutide's incretin/glucagon approach: Tesamorelin the GHRH analog with the most rigorous clinical research base in the category (Falutz 2007 NEJM
2019 Cochrane Review: A Cochrane review of RCTs on ALCAR for diabetic peripheral neuropathy concluded very low-certainty evidence (GRADE system) indicating uncertainty regarding short-term pain relief, but noted potential improvements in nerve conduction velocity
Approvals for cardiovascular risk reduction and ongoing trials in Alzheimer's disease, sleep apnea, and depression are dramatically widening the addressable population
HSA and FSA accounts cover treatment, no insurance is required, and PlexusDx serves all 50 states